Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2024) 99 RC2.6 | DOI: 10.1530/endoabs.99.RC2.6

1University of Ferrara, Section of Endocrinology and Internal Medicine, Department of Medical Sciences, Ferrara, Italy; 2University of Ferrara, Ferrara, Italy; 3University Hospital of Ferrara, Laboratorio Unico Provinciale, Ferrara, Italy; 4University Hospital of Ferrara, Regional HUB Centre for Thalassaemia and Haemoglobinopathies, Department of Medicine, Ferrara, Italy


Introduction: Patients with transfusion-dependent β-thalassemia (TDT) frequently exhibit elevated urinary calcium excretion, contributing to kidney stone formation and osteoporosis. The underlying mechanism of hypercalciuria in β-thalassemia remains elusive, with FGF23 playing a potential role. FGF23, a bone-derived hormone, primarily acts on the kidneys by inhibiting phosphate reabsorption in the proximal tubules while enhancing calcium uptake in the distal tubules. Few studies have evaluated FGF23 levels in β-thalassemic patients as compared to the general population with contradictory results.

Objective: This study aims to investigate FGF23 levels in patients with TDT and hypercalciuria vs those without.

Methods: Our study included 126 patients referring to the Regional HUB Centre for Thalassaemia and Haemoglobinopathies in Ferrara in 2023. The parameters we assessed are shown in the Table. Hypercalciuria was defined as a 24-hour urinary calcium level ≥4 mg/kg/day. The intact FGF23 polypeptide was quantified using the chemiluminescence immunoassay "LIAISON® FGF 23 test".

Results:

NormocalciuricHypercalciuric
N=12639 (31%)87 (69%)
Sex (F/M)27/1244/43
Median [IQR]Median [IQR]
Age (years)51 [45; 56]49 [44; 53]
BMI (kg/m2) *23.8 [21.4; 26.7]21.9 [20.2; 24.8]
FGF23 (pg/ml) **42.6 [30.1; 58.7]32.5 [23.8; 42.7]
Urinay creatinine (g/day) *0.9 [0.8; 1.1]1.1 [0.8; 1.4]
Urinary phosphate (g/day) ***0.55 [0.3; 0.7]0.8 [0.6; 1]
Urinary proteins (mg/day)131 [101; 207]176 [114; 242]
Calcium (mg/dl)9.3 [9; 9.7]9.5 [9.3; 9.8]
Phosphate (mg/dl)3.6 [3.2; 3.9]3.5 [3.3; 3.9]
Vitamin D (ng/ml) *34.9 [27.2; 37.5]28.8 [19.4; 34.6]
PTH (pg/ml)28 [21.5; 41.5]25 [19; 33.8]
Magnesium (mg/dl)2.2 [2; 2.4]2.1 [2; 2.3]
Ferritin (ng/ml)548 [334; 889]447 [298; 676]
ron (ug/dl)223.5 [195.8; 272.3]241 [215.5; 270]
eGFR (ml/min)91.6 [75; 109]90.8 [77.1; 116.7]
Creatinine (mg/dl)0.74 [0.59; 0.89]0.73 [0.61; 0.9]
Mann-Whitney test was applied. P<0.05*; P<0.01**; P<0.001***

Conclusions: Hypercalciuric patients exhibited lower FGF23 levels combined with higher urinary creatinine and phosphate levels as compared to normocalciuric patients. This smggests a potential role of FGF23 in the development of hypercalciuria, but additional mechanisms (i.e., renal impairment due to iron overload or chelation therapy) may contribute to the increased phosphate and calcium renal losses in these patients. Further studies are warranted to better explore this issue.

Volume 99

26th European Congress of Endocrinology

Stockholm, Sweden
11 May 2024 - 14 May 2024

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.